Telix Pharmaceuticals (ASX:TLX) is positioning a new generation of PSMA-targeted therapies to overcome limitations seen when first-generation radioligand therapies are moved into earlier lines of prostate cancer care.
The company’s scientific update to investors presents a dual strategy that pairs an antibody-based radioconjugate for late-stage disease with a highly targeted small molecule designed for earlier hormone-sensitive disease, and uses clinical and imaging data to argue for a rethink of dose and timing.
The presentation acknowledges the established role of 177Lu PSMA small molecule therapies in advanced metastatic castration resistant prostate cancer while calling out emerging concerns when those same agents are applied to healthier patients.
Quality of life and renal and salivary gland toxicity are central issues. Clinicians have expressed concern about worsened quality of life and potential overtreatment with fixed multi-dose regimens.
Telix says its portfolio response is twofold. For metastatic castration-resistant patients, the company is advancing TLX591, a radio antibody drug conjugate intended to exploit antibody selectivity and extended tumour retention, for combination with standard of care in a two-dose regimen. For earlier metastatic hormone-sensitive patients, the company highlights TLX597 Tx, a next-generation small-molecule radioligand engineered for low kidney and salivary gland uptake and long tumour retention, attributes that, the company argues, enable dose intensification and better quality-of-life outcomes.
An investigator-initiated Phase 2 study has dosed over 85 patients with TLX597 and tested an intensified early-dosing schedule that concentrates three high-activity doses within the first 15 days, followed by longer intervals. The rationale is that the first dose induces PSMA upregulation in tumours and that subsequent closely timed doses therefore deliver greater radiation when cancer cells are most vulnerable. Representative imaging and case summaries show marked PSA declines and lesion shrinkage, including examples of 85 per cent PSA reductions and individual patients with 97 per cent PSA responses.
The comparative tables and SPECT images presented indicate substantially lower absorbed doses to the kidneys and salivary glands with TLX597 relative to other agents, while showing higher lesion doses and persistent tumour signal at later time points after injection. These biodistribution and pharmacokinetic features are used to justify an intensified front-loaded regimen and to support exploration of adaptive schedules in earlier disease, where preserving quality of life is paramount.
Telix also outlines a path to test TLX597 in the hormone-sensitive population through a Phase 2a adaptive study called OPTIMAL E. That protocol pairs TLX597 with contemporary androgen receptor pathway inhibitors and uses a three-dose loading phase followed by adaptive cycles based on response to avoid overtreatment while maximising benefit in responders. The company highlights the potential to integrate novel isotopes, including alpha emitters, in the future to broaden therapeutic options.